Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving fixed or stabilized – nonliving microorganism,...
Reexamination Certificate
2011-06-14
2011-06-14
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving fixed or stabilized, nonliving microorganism,...
Reexamination Certificate
active
07960138
ABSTRACT:
Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.
REFERENCES:
patent: 4485086 (1984-11-01), Wong
patent: 4783529 (1988-11-01), Lavallee et al.
patent: 4857300 (1989-08-01), Maksem
patent: 4930516 (1990-06-01), Alfano
patent: 5004811 (1991-04-01), Bommer
patent: 5162231 (1992-11-01), Cole et al.
patent: 5391547 (1995-02-01), Cole et al.
patent: 6190877 (2001-02-01), Adair
patent: 6316215 (2001-11-01), Adair et al.
patent: 6838248 (2005-01-01), Garwin
patent: 6984498 (2006-01-01), Adair
patent: 7384764 (2008-06-01), Garwin
patent: 7670799 (2010-03-01), Garwin
patent: 2006/0058683 (2006-03-01), Chance
patent: 2007/0172392 (2007-07-01), Sen
patent: 2009/0004690 (2009-01-01), Garwin
patent: WO91/19977 (1991-12-01), None
patent: WO02/42267 (2002-05-01), None
Berns, Michael W. et al., “In Vitro Cellular Effects of Hematoporphyrin Derivative”,Cancer Researchvol. 42, No. 6 1982 , 2325-2328.
Boring, Catherine C. , “Cancer Statistics”,CA Cancer J Clinvol. 43, No. 1 1993 , 7-26.
Bunseki, Kagaku , “Reversed-Phase Partition Chromatography for Trace Copper (II), Zinc (II), Manganese (II), and Cobaldt (II) Using Tetrakis (4-Carboxyphenyl) Porphine”,The Japan Society for Analytical Chemistryvol. 35, No. 9 1986 , 829-831.
Clarke, Suzanne E. et al., “Aqueous Complexation Equilibria of Meso Tetrakis(4-carboxyphenyl)porphyrine with Violgens”,J of Physical Chemistryvol. 106, No. 13 2002 , 3235-3242.
Cole, D. A. et al., “Copper-67 Labeled Porphyrin Localization in Inflamed Tissue”,Copper Bioavailability and Metabolism1990 , 259-272.
Cole, D. A. et al., “The Biological Characteristics of a Water Soluble Porphyrin in Rat Lymph Nodes”,Nucl. Med. Biol. Vole. 17, No. 5 1990 , 457-464.
Cortese, Denis A. et al., “Hematoporphyrin Derivative in the Detection and Localization of Radiographically Occult Lung Cancer”,Am. Rev. Respir. Dis. vol. 126, No. 1 1992 , 1087-1088.
Dellinger, M. et al., “Cellular Uptake of Hydroxyethylvinyldeuteroporphyrin and Photoinactivation of Cultivated Human Leukemia (REH6) Cells”,Biological Abstracts, 82:8, 1986, Philadelphia, PA, US; Abstract No. 75075, Abstract page AB-679 of Photochem. Photobiol., 43:6 1986 , 639-648.
Ferguson, Mark K. , “Diagnosing and Staging on Non-Small Cell Lung Cancer”,Hematol Oncol Clin N AMvol. 4, No. 6 1990 , 1053-1068.
Firnau, G. et al., “Cu Labeling of Hematoporphyrin Derivative for Non-Invasive In-Vivo Measurement of Tumor Uptake”,Porphyrin Localization and Treatment of Tumors1984 , 629-636.
Hambright, P. et al., “The Distribution of Various Water Soluble Radioactive Metalloporphyrins in Tumor Bearing Mice”,Bioinorganic Chemistryvol. 5 1975 , 87-92.
Haroske, G. et al., “Frequency and Diagnostic Reliabilty of Subvisual Morphologic Markers for Malignancy in the Cervical Epithelium”,Arch Geschwulstforschvol. 58, No. 3 1988 , 159-168.
Hirsch, Fred R. et al., “Prevention and Early Detection of Lung Cancer-Clinical Aspects”,Lung Cancervol. 17 1997 , 163-174.
Hutchinson, Martha L. et al., “Measurement fo Subvisual Changes in Cervical Squamous Metaplastic Cells for Detecting Abnormality”,Anal. Quant. Cytol. Estol.vol. 14, No. 4 1992 , 330-334.
Kato, Harubumi et al., “Early Detection of Lung Cancer by Means of Hematoporphyrin Derivative Fluorescence and Laser Photoradiation”,Clinics in Chest Medicinevol. 6, No. 2 1985 , 237-253.
Mao, Li et al., “Detection of Oncogene Mutations in Sputum Precedes Diagnosis of Lung Cancer”,Cancer Researchvol. 54 1994 , 1634-1637.
Mao, Li et al., “Microsatellite Alterations as Clonal Markers for the Detection of Human Cancer”,Proc. Natl. Acad. Sci.vol. 91 1994 , 9871-9875.
Mercer-Smith, Janet A. et al., “The Development of Copper-67-Labeled Porphyrin-Antibody Conjugates”,Targeted Diagnosis and Therapyvol. 1 1988 , 317-352.
Moan, J. et al., “A Change is the Qauntum Yield of Photoinactivation of Cells Observed During Photodynamic Treatment”,Biological Abstracts, 86:7, 1988, Philadelphia, PA, US; Abstract No. 72079; Abstract p. AB-772 of Lasers Med. Sci., 3:2 1988 , 93-98.
Moan, J. et al., “Photosensitizing Efficiencies, Tumor and Cellular Uptake of Different Photosensitizing Drugs Relevant for Photodynamic Therapy of Cancer”,Biological Abstracts, 85:5, 1988, Philadelphia, PA, US; Abstract No. 49732; Abstract p. AB-723 of Photochem. Photobiol., 46:5 1987 , 713-722.
Moan, J. et al., “The Mechanism of Photodynamic Inactivation of Human Cells in Vitro in the Presence of Haematoporphyrin”,Biological Abstracts, 68:10, 1979, Philadelphia, PA, US; Abstract No. 62117; Abstract p. 6230,BR J. Cancer, 39:4 1979 , 398-407.
Montag, Anthony G. et al., “Karyometric Features in Nuclei Near Colonic Adenocarcinoma”,Anal. Quant. Cytol. Histol.vol. 13 1991 , 159-167.
Musser, David A. et al., “The Binding of Tumor Localizing Porphyrins to a Fibrin Matrix and Their Effects Following Photoirradiation”,Res. Comm. In Chem. Path. And Pharm.vol. 28, No. 3 1980 , 505-525.
Patel, K. B. , “Fluorescing Cells in Sputum After Parenteral HPD”,Porphyrin Localization and Treatment of Tumors1984 , 521-530.
Pegaz, B. et al., “Effect of the Lipophilicyt on the Phtothrombic Activity of Biodegradable Nanoparticles Loaded with Porphyrin Derivatives”,TNT2004Sergovia Spain 2004 , 1-2.
Roberts, Jeanette C. et al., “Preparation and Characterization of Copper-67 Porphyrin-Antibody Conjugates”,Journal of Immun. Methodsvol. 105 1987 , 153-164.
Roby, Tina J. et al., “Discriminant Analysis of Lower Respiratory Tract Components Associated with Cigarette Smoking, Based on Quantitative Sputum Cytology”,Acta Cytolvol. 34 1990 , 147-154.
Roby, Tina J. et al., “Reliability of a Quantitative Interpretation of Sputum Cytology Slides”,Acta Cytolvol. 34 1990 , 140-146.
Schumann, G. B. et al., “Quantitative Sputum Cytologic Findings in 109 Nonsmokers”,Am Rev Respr Disvol. 139 1989 , 601-603.
Shulok, Janine R. et al., “Subcellular Localization of Hematoporphyrin Derivative in Bladder Tumor Cells in Culture”,Photochem and Photobiolvol. 51, No. 4 1990 , 451-457.
Sidransky, David , “Importance of Chromosome 9p Loss in Human Lung Cancer”,J Natl Cancer Instvol. 87 1995 , 1201-1202.
Tockman, Melvyn S. et al., “Sensitive and Specific Monoclonal Antibody Recognition of Human Lung Cancer Antigen on Preserved Sputum Cells: A New Approach to Early Lung Cancer Detection”,J Clin Oncolvol. 11 1988 , 1685-1693.
Tockman, Melvyn S. , “The Early Detection of Second Primary Lung Cancers by Sputum Immunostaining”,Chestvol. 106 1994 , 385s-390s.
Wingo, Phyllis A. et al., “Cancer Statistics”,CA Clinical J Clinvol. 45 1995 , 8-30.
Biomoda, Inc.
Gitomer Ralph
Peacock & Myers, P.C.
Vilven-Doggett Janeen
LandOfFree
Method for prognosing response to cancer therapy with 5, 10,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for prognosing response to cancer therapy with 5, 10,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for prognosing response to cancer therapy with 5, 10,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2746038